Xolair 300 MG/2 ML syringe 2ML

Ended Awarded

Contract number
SPE2DR26FSCW7
Awardee
Awarding agency
Obligated
$4,761

Award facts

Contract value 100% obligated
$4,761.09 Current and potential, with all options
Completion date 100% complete
Current and potential, with all options
NAICS code
424210 Drugs and Druggists' Sundries Merchant Wholesalers
PSC
6505 Drugs And Biologicals
Set-aside
No set-aside
Competition
Full and Open Competition Negotiated Proposal / Quote
Pricing
Firm Fixed Price
Place of performance
Park Ridge, IL 60068, USA

Award details come from SAM.gov/FPDS.

About this award

The Defense Logistics Agency issued a $4,761.09 delivery order to DMS Pharmaceutical Group Inc. on July 13, 2026, for Xolair 300 mg/2 ml syringes under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V).

DMS Pharmaceutical is a woman-owned small business holding the single-award indefinite delivery contract SPE2DX under PPV-G GEN V, authorized to supply branded and generic prescription drugs, biologics, and medical consumables to Department of Defense military healthcare facilities worldwide. Place of performance is Park Ridge, Illinois. The order is firm fixed price with an ultimate completion date of August 3, 2026.

Quick answers

Who was awarded contract SPE2DR26FSCW7?

SPE2DR26FSCW7 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on July 13, 2026.

How much is contract SPE2DR26FSCW7 worth?

The government has obligated $4,761 on SPE2DR26FSCW7.

Is contract SPE2DR26FSCW7 an order under another contract?

Yes. SPE2DR26FSCW7 is a delivery order under SPE2DR25D9316, an indefinite delivery contract.

Was contract SPE2DR26FSCW7 competed?

The extent of competition for SPE2DR26FSCW7 was full and open competition.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award